XNApharma GmbH
Dr. Tobias Pöhlmann
Ronneburger Straße 74
07546 Gera

Phone: +49 365 77347180
https://xnapharma.com

XNApharma -
Oligonucleotides for life.
  • zoom website
  • print preview

Developing oligonucleotide therapies

Technology platform

Target cell specificity is the key for a highly potent and well tolerated cancer therapy. XNApharma is developing oligonucleotides which are selectively active in cancer cells.

Find out more

Preclinical development and clinical strategy

The Peptide-siRNA prodrugs allow specific targetting of cancer cells. XNApharma develops a drug candidate pipeline based on this technology to treat ovary cancer as a first indication.

Find out more

Oligonucleotide development as service

XNApharma offers its experience in oligonucleitode drug development as service, including sequence optimization, formulation, ADME and preparation for GMP.

Find out more

Source: https://xnapharma.com/

Science dedicated to human health

Science dedicated to human health

XNApharma Gera
Copyright© XNApharma GmbH

Contact information

XNApharma GmbH
Ronneburger Straße 74
07546 Gera | Germany

Phone: +49 365 77347180
 
Manage your consents

Use the website comfortably and informatively - Agree now!

To make your visit to this website as comfortable and informative as possible, we use cookies and online services of third parties. For data protection reasons, these third-party online services (including cookies) may only be used after you have given your consent. Which online services are involved can be found in the details / settings or in the privacy policy. You can also revoke consents already granted here.